MedTrace Logo

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

NCT00747123 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-10-03

Study results available
· View outcomes & findings →

Summary

Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.

Conditions

Interventions

BIOLOGICAL

ACE-011

ACE-011 given by the subcutaneous route of administration monthly for 4 doses.

BIOLOGICAL

Placebo

Placebo given by the subcutaneous route of administration monthly for 4 doses.

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Abderrahmane Laadem, MD · Celgene Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-01
Primary Completion
2009-08-01
Completion
2009-08-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00747123 on ClinicalTrials.gov